泌尿道癌 抗癌藥物治療指 討論日期 團隊討論 : 105 年 10 月 20 日 三院討論 : 105 年 12 月 7 日 團隊確認 : 106 年 2 月 9 日 核備日期 : 106 年 月 18 日
攝護腺癌抗癌藥物治療指 Men with High-Volume, ADT-naïve, Metastatic Disease Docetaxel without Prednisolone with ADT 參考文獻 1, 2 Docetaxel 75 1 6 參考文獻 2, 3 Docetaxel 30 1 QW Men with Symptomatic mcrpc First-line Therapy Docetaxel with/without Prednisolone 參考文獻 1, 2 Docetaxel 75 1 10 Prednisolone 5 mg PO BID 參考文獻 2, 3 Docetaxel 30, 15, 22, 29 Q6W 5 Prednisolone 5 mg PO BID 泌尿道腫瘤抗癌藥物治療指
Alternative Chemotherapy Mitoxantrone with Prednisolone 參考文獻 2 Mitoxantrone Prednisolone 12 5 mg PO BID 1 Cabazitaxel Prednisolone 藥品名劑量 /m 2 25 10 mg PO QD 參考文獻 1 10 參考文獻 1. Http://centerformenshealth.com/center--mens-health/new-treatment-now-available-that-extends-life-in-men-with-highlyadvanced-prostate-cancer The study results of ECOG 3805 demonstrating OS benefit with early docetaxel chemotherapy may change standard of care in patients with extensive disease metastatic prostate cancer 2. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 200;351:1502-1512. 3. Takahiro Kojima, Toru Shimazui, Mizuki Onozawa, Sadamu Tsukamoto, Shiro Hinotsu, et al. Weekly Administration of Docetaxel in Patients with Hormonerefractory Prostate Cancer: a Pilot Study on Japanese Patients. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:117-115. 26
膀胱癌抗癌藥物治療指 Perioperative Chemotherapy (neoadjuvant or adjuvant) and 參考文獻 1, 2 1000 70 1 藥品名劑量 /m 2 1000 35 藥品名劑量 /m 2 1000 35 參考文獻 1, 2 參考文獻 1, 2 1, 2 泌尿道腫瘤抗癌藥物治療指 藥品名劑量 /m 2 1000 70 參考文獻 1, 2, 15 QW 6 1 QW 6 27
CMV 參考文獻 3 Methotrexate 30 3 Vinblastine 3 100 2 3 Folinic acid 15 mg Q6H 2, 9 3 Adjuvant intravesical treatment 參考文獻 BCG 81mg Intravesical QW 3 參考文獻 5~7 Mitomycin 20~0mg Intravesical QW 1~6 參考文獻 16 Doxorubicin 0mg Intravesical Intravesical MDP regimen 參考文獻 8~12 給藥日 頻 週期 Mitomycin 30mg Intravesical 1 2 cycles, maintenance Doxorubicin 30mg Intravesical 8 protocol were given at 3, 6, 12, 18, 2, 30, 30mg Intravesical 15 and 36 months 28
Chemotherapy for Metastatic Disease First-line Therapy and cisplatin 參考文獻 2, 13 800~1000 50~70 2 and carboplatin 參考文獻 2, 13 Carboplatin 800~1000 ~5 AUC 1 DDMVAC with growth factor support 參考文獻 1, 15 Methotrexate 30 1 or 2 Q2W 3 or Vinblastine 3 1 or 2 Q2W 3 or Doxorubicin 20-30 1 or 2 Q2W 3 or 50-70 1 Q2W 3 or 泌尿道腫瘤抗癌藥物治療指 參考文獻 1, 15 Methotrexate 30 1 or 2 Q2W 3 or Vinblastine 3 1 or 2 Q2W 3 or Doxorubicin 20~30 1 or 2 Q2W 3 or Carboplatin ~5 AUC 1 Q2W 3 or 29
Radiosensitizing chemotherapy regimens for bladder-preserving chemoradiation following a maximal TURBT First-line Therapy and 5-FU 參考文獻 10 5-FU 15 00 1-3, 8-10, 15-17 1-3, 8-10, 15-17 5-FU and Mitomycin C 參考文獻 9 Mitomycin C 5-FU 12 500 1 1-5, 16-20 and paclitaxel 參考文獻 10 Paclitaxel 15 50 1-3, 8-10, 15-17 1-3, 8-10, 15-17 泌尿道腫瘤抗癌藥物治療指 參考文獻 1. Dash A, Pettus JA, Herr HW, et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008;113:271-277. 2. Von der Maase H, Hansen SW, Roberts JT, et al. and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J 250
Clin Oncol 2000;18:3068-3077. 3. Griffiths G, Hall R, Sylvester R, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 3089 trial. J Clin Oncol 2011;29:2171-2177.. Lamm DL1, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000; 163: 112-9 5. Lundholm C1, Norlén BJ, Ekman P, et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol. 1996; 156: 372-6 6. Solsona E, Iborra I, Ricos JV, et al: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 1999; 161:1120-1123. 7. Witjes JA1, v d Meijden AP, Collette L, et al. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology. 1998 ; 52: 03-10 8. Tunio MA, Hashmi A, Qayyum A, et al. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys. 2012; 82: e57-62 9. James ND, Hussain SA, Hall E, et al; BC2001 Investigators. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366:177-188 10. Mitin T, Hunt D, Shipley W, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracilcisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomized multicentre phase 2 trial. Lancet Oncol 2013;1:863-872. 11. Lamm DL1, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000; 163: 112-9 12. Lundholm C, Norlén BJ, Ekman P, et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol. 1996 Aug;156:372-6 泌尿道腫瘤抗癌藥物治療指 251
13.Von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:602-608. 1. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 3092. J Clin Oncol 2001;19:2638-266. 15. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006;2:50-5. 泌尿道腫瘤抗癌藥物治療指 252